LDLR and liver cancer: Benefiting from linker-based therapeutic agent binding, Wang et al. introduced a therapeutic conformation to low-density lipoprotein receptor (LDL-R) as a biomarker target on the surface of cancer cells, such as Huh-7 liver cancer cells and MDA-MB-231 breast cancer cells [29].